#China #Hong Kong #Akeso #Ivonescimab #NSCLC

Ivonescimab: Advancing Lung Cancer Treatment without Chemotherapy

In a groundbreaking presentation at the 2026 European Lung Cancer Congress (ELCC), Akeso, Inc. announced compelling data from its HARMONi-2 study, which evaluated the innovative therapy Ivonescimab as a first-line treatment for patients with PD-L1 positive non-small cell lung cancer (NSCLC). This revolutionary medication, a first-in-class bispecific antibody targeting both PD-1 and VEGF, has shown not just efficacy but significant improvements in patients' health-related quality of life (HRQoL).

Study Overview

The HARMONi-2 trial directly compared Ivonescimab to Pembrolizumab, a well-established treatment. The results were impressive: Ivonescimab demonstrated a median progression-free survival (PFS) of 11.14 months, substantially longer than the 5.82 months associated with Pembrolizumab. This finding, indicative of a 49% decrease in the risk of disease progression or death, showcases Ivonescimab’s potential as a promising standard of care for NSCLC patients.

Quality of Life Metrics

Exploring beyond mere survival rates, the study focused on the crucial aspect of HRQoL using validated assessment tools including QLQ-C30, QLQ-LC13, and EQ-5D-5L.

• - Global Health Status: Patients treated with Ivonescimab exhibited sustained improvements in their global health and functional status, with the median time to deterioration not reached, compared to 9.9 months for those receiving Pembrolizumab. Additionally, the 12-month deterioration-free rate for Ivonescimab was an encouraging 51% versus 46% for its competitor.
• - Symptom Control: Patients in the Ivonescimab group reported notable reductions in key symptoms of lung cancer. The median time to deterioration for cough and dyspnea was not reached, with significant mean score improvements, indicating better overall symptom management, contributing to enhanced quality of life.

Health Utility Values

On the EQ-5D-5L visual analog scale, which measures health utility, patients on Ivonescimab also saw improvements from a score of 81.9 at baseline to 84.3 at 12 weeks, maintaining high values thereafter. This consistent performance suggests that Ivonescimab positively impacts patient well-being over time, establishing it as a more favorable treatment option without the burdens of chemotherapy.

Implications for Clinical Practice

These results provide robust evidence validating Ivonescimab's broad clinical use, setting a new benchmark for first-line treatments in non-small cell lung cancer. The favorable safety profile of Ivonescimab, combined with its significant efficacy and HRQoL benefits, positions it as a revolutionary therapy in modern oncology, moving away from traditional chemotherapy regimens.

With Ivonescimab now an approved treatment in China for PD-L1 positive NSCLC, its clinical utility has been recognized not just in trials but through real-world experiences across a vast number of patients. This medicinal breakthrough underscores Akeso's commitment to developing innovative solutions that address the needs of patients battling major diseases.

Akeso's Vision

Established in 2012, Akeso has been at the forefront of biopharmaceutical innovation, striving to develop and commercialize first-in-class therapies. The success of Ivonescimab reflects the company's dedication to integrating advanced technologies and research to create effective and safe treatment options for patients worldwide. Akeso continues to invest heavily in research and development, with numerous ongoing trials aimed at exploring further therapeutic avenues in cancer and other significant health conditions.

In conclusion, positive HRQoL data from the HARMONi-2 study signifies a major stepping stone in oncology and highlights Ivonescimab's role in reshaping lung cancer treatment without the need for chemotherapy, ultimately improving patient care and outcomes in NSCLC.